Evidence map›Paper›PMID 28470573›Full record

ArticlePathology oncology research : POR2018

BSND is a Novel Immunohistochemical Marker for Oncocytic Salivary Gland Tumors.

Kazuya Shinmura, Hisami Kato, Yuichi Kawanishi, Takaharu Kamo, Yusuke Inoue, Katsuhiro Yoshimura, Kenta Sugiyama, Kiyoshi Misawa, Seiji Hosokawa, Hiroyuki Mineta and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Salivary gland hamartoma with eosinophilic cell adenoma: a clinicopathologic analysis of two cases.International journal of clinical and experimental pathology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kazuya ShinmuraDepartment of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, 431-3192, Japan. kzshinmu@hama-med.ac.jp.ORCID http://orcid.org/0000-0003-4963-746X
Hisami KatoDepartment of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, 431-3192, Japan.
Yuichi KawanishiAdvanced Research Facilities and Services, Preeminent Medical Photonics Education and Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Takaharu KamoDepartment of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, 431-3192, Japan.
Yusuke InoueDepartment of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, 431-3192, Japan.
Katsuhiro YoshimuraDepartment of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, 431-3192, Japan.
Kenta SugiyamaDepartment of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, 431-3192, Japan.
Kiyoshi MisawaDepartment of Otolaryngology/Head and Neck Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Seiji HosokawaDepartment of Otolaryngology/Head and Neck Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hiroyuki MinetaDepartment of Otolaryngology/Head and Neck Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Haruhiko SugimuraDepartment of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, 431-3192, Japan.
Hamamatsu University School of Medicine · JP

Funding

Japan Society for the Promotion of Science 25460476Ministry of Education, Culture, Sports, Science and Technology 221S0001Ministry of Health, Labour and Welfare 21-1
6 · The paper itself

Abstract

BSND protein, which is involved in chloride transport, is expressed in normal kidney and the inner ear and is known as an immunohistochemical marker for chromophobe renal cell carcinoma (RCC) and renal oncocytoma; however, other organs and tumor types exhibiting BSND expression have not yet been reported. In this study, we investigated the expression of BSND using data from the Cancer Genome Atlas (TCGA) database and by performing immunohistochemical analyses. As a result, we found that BSND was also expressed in the striated duct cells of normal salivary glands. Next, BSND expression was examined immunohistochemically in 7 types of salivary gland tumors, and BSND positivity was found in Warthin's tumor (25 out of 25 cases; 100%) and oncocytoma (4/4; 100%), both of which are usually classified as oncocytic tumors, whereas BSND negativity was observed for pleomorphic adenoma (0/11), adenoid cystic carcinoma (0/7), acinic cell carcinoma (0/6), mucoepidermoid carcinoma (0/6), and salivary duct carcinoma (0/5). Finally, the expression of BSND mRNA in 30 types of tumors other than chromophobe RCC and salivary gland tumors was examined using data from the TCGA database, but none of these tumors exhibited BSND expression. These results suggest that BSND is expressed only in normal salivary glands and oncocytic salivary gland tumors such as Warthin's tumor and oncocytoma in addition to the two known organs and the two known renal tumor types mentioned above. The selective expression pattern of BSND suggests that BSND is an excellent novel immunohistochemical marker for oncocytic salivary gland tumors.

Indexed as

Adenoma, OxyphilicAdultAgedBiomarkers, TumorChloride ChannelsFemaleHumansImmunohistochemistryMaleMiddle AgedSalivary Gland NeoplasmsBiomarkers, TumorBSND protein, humanChloride ChannelsBSNDImmunohistochemical markerOncocytic salivary gland tumorOncocytomaWarthin’s tumor

Identifiers

PMID28470573
OpenAlexW2611077918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.